Findings
In this phase 3 randomized clinical trial including 2247 adolescents, neutralizing antibody responses were noninferior compared with those of young adults aged 18 to 25 years (effectiveness). Vaccine efficacy was 79.5%, and reactogenicity was mostly mild to moderate and transient; no safety concerns were identified.